Author

Y.-A. Shen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1

Frequent Co-Authors

T.-L. Wang· 2 shared A. Chaidos· 1 shared A. Karadimitris· 1 shared A. Katsarou· 1 shared B. Bergonia· 1 shared C.-M. Chuang· 1 shared F.-C. Hsu· 1 shared G. D. Shimberg· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

T.-L. Wang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systems medicine dissection of chromosome 1q amplification reveals oncogenic regulatory circuits and informs targeted therapy in cancer

N. Trasanidis, A. Katsarou, K. Ponnusamy, Y.-A. Shen, I. V. Kostopoulos, B. Bergonia, K. Keren, P. Reema, X. Xiao, R. M. Szydlo, P. M. Sabbattini, I. A. Roberts, H. W. Auner, K. N. Naresh, A. Chaidos, , A. Karadimitris

This study identifies oncogenic regulatory circuits driven by chromosome 1q amplification in cancer and proposes targeted therapy strategies using a systems medicine approach.

bioRxiv · Nov 17, 2021Cancer Biology

Development of Small Molecule Inhibitors Targeting PBX1 Transcription Signaling as a Novel Cancer Therapeutic Strategy

T.-L. Wang, I.-M. Shih, Y.-A. Shen, J. Jung, G. D. Shimberg, F.-C. Hsu, Y. S. Rahmanto, S. L. Gaillard, J. Hong, J. Bosch, C.-M. Chuang

This study develops small molecule inhibitors targeting PBX1 transcription signaling, showing they suppress cancer cell growth and re-sensitize resistant tumors.

bioRxiv · Apr 19, 2021Pathology